Immunotoxicity profile of natalizumab

References

• Arroyo, A. G., Yang, J. T., Rayburn, H., and Hynes, R. O. 1996. Differential requirements for α4 integrins during fetal and adult hematopoiesis. Cell 85:997–1008.
   PubMed Web of Science ®Google Scholar
• Arroyo, A. G., Yang, J. T., Rayburn, H., and Hynes, R. O. 1999. α4 integrins regulate the proliferation/differentiation balance of multi-lineage hematopoietic progenitors in vivo. Immunity. 11:555–566.
   PubMed Web of Science ®Google Scholar
• Banerjee, E. R., Latchman, Y. E., Jiang, Y., Priestley, G. V., and Papayannopoulou, T. 2008. Distinct changes in adult lymphopoiesis in Rag2−/- mice fully reconstituted by α4-deficient adult bone marrow cells. Exp. Hematol. 36:1004–1013.
   Google Scholar
• Christensen, B. E., Jønsson, V., Matre, R., and Tønder, O. 1978. Traffic of T- and B-lymphocytes in the normal spleen. Scand. J. Haematol. 20:246–257.
   PubMedGoogle Scholar
• Danese, S., Semeraro, S., Marini, M., Roberto, I., Armuzzi, A., Papa, A., and Gasbarrini, A. 2005. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Dig. Liver. Dis. 37:811–818.
   PubMedGoogle Scholar
• Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., and Donoghue, S. 2003. Natalizumab for active Crohn’s disease. N. Engl. J. Med. 348:24–32.
   PubMed Web of Science ®Google Scholar
• Gordon, F. H., Lai, C. W., Hamilton, M. I., Allison, M. C., Srivastava, E. D., Fouweather, M. G., Donoghue, S., Greenlees, C., Subhani, J., Amlot, P. L., and Pounder, R. E. 2001. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn’s disease. Gastroenterology 121:268–274.
   PubMed Web of Science ®Google Scholar
• Heilbronn, R., Albrecht, I., Stephan, S., Bürkle, A., and zur Hausen, H. 1993. Human cytomegalovirus induces JC virus DNA replication in human fibroblasts. Proc. Natl. Acad. Sci. USA 90:11406–11410.
   PubMedGoogle Scholar
• Hyams, J. S., Wilson, D. C., Thomas, A., Heuschkel, R., Mitton, S., Mitchell, B., Daniels, R., Libonati, M. A., Zanker, S., and Kugathasan, S. 2007. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 44:185–191.
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters, B.K., and Tyler, K.L. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med. 353:369–374.
   PubMed Web of Science ®Google Scholar
• Knowles, D. M., Cesarman, E., Chadburn, A., Frizzera, G., Chen, J., Rose, E. A., and Michler, R. 1995. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of post-transplantation lymphoproliferative disorders. Blood 85:552–565.
   PubMed Web of Science ®Google Scholar
• Langer-Gould, A., Atlas, S.W., Green, A.J., Bollen, A.W., and Pelletier, D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353:375–381.
   PubMed Web of Science ®Google Scholar
• Lasky, L. A. 1996. Hematopoiesis: Wandering progenitor cells. Curr. Biol. 6:1238–1240.
   Google Scholar
• Meropol, N. J., Porter, M., Blumenson, L. E., Lindemann, M. J., Perez, R. P., Vaickus, L., Loewen, G. M., Creaven, P. J., Wilkes, K. A., Giedlin, M. A., and Caligiuri, M. A. 1996. Daily subcutaneous injection of low-dose interleukin-2 expands natural killer cells in vivo without significant toxicity. Clin. Cancer. Res. 2:669–677.
   PubMed Web of Science ®Google Scholar
• Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., and O’Connor, P. W. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15–23.
   PubMed Web of Science ®Google Scholar
• Mirandola, P., Ponti, C., Gobbi, G., Sponzilli, I., Melloni, E., and Vitale, M. 2004. The response of human natural killer cells to interleukin-2. J. Endocrinol. Invest. 27 (S6):146–150.
   Google Scholar
• Naume, B., and Espevik, T. 1991. Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. J. Immunol. 147:2208–2214.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information (NCBI). GenBank accession number XM 001100929. http://www.ncbi.nlm.nih.gov. Accessed 26 March 2009.
   Google Scholar
• Oostendorp R. A., and Dörmer, P. 1997. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Leuk. Lymphoma 24:423–435.
   PubMed Web of Science ®Google Scholar
• Polman, C. H., O’Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899–910.
   PubMed Web of Science ®Google Scholar
• Qian, H., Georges-Labouesse, E., Nyström, A., Domogatskaya, A., Tryggvason, K., Jacobsen, S. E., and Ekblom, M. 2007. Distinct roles of integrins α6 and α4 in homing of fetal liver hematopoietic stem and progenitor cells. Blood 110:2399–2407.
   PubMedGoogle Scholar
• Robinson, B. W., and Morstyn, G. 1987. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells. Cell. Immunol. 106:215–222.
   PubMedGoogle Scholar
• Rose, D. M., Han, J., and Ginsberg, M. H. 2002. α4 integrins and the immune response. Immunol. Rev. 186:118–124.
   PubMed Web of Science ®Google Scholar
• Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354:911–923.
   PubMed Web of Science ®Google Scholar
• Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., van Deventer, S., Goldblum, R., Despain, D., Hogge, G. S., and Rutgeerts, P. 2005. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 353:1912–1925.
   PubMed Web of Science ®Google Scholar
• Sands, B. E., Kozarek, R., Spainhour, J., Barish, C. F., Becker, S., Goldberg, L., Katz, S., Goldblum, R., Harrigan, R., Hilton, D., and Hanauer, S. B. 2007. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm. Bowel. Dis. 13:2–11.
   PubMed Web of Science ®Google Scholar
• Schmidtko, J., Wang, R., Wu, C., Mauiyyedi, S., Harris, N., Della Pelle, P., Brousaides, N., Zagachin, L., Ferry, J., Wang, F., Kawai, T., Sachs, D., Cosimi, B.,,and Colvin, R. 2002. Post-transplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 73:1431–1439.
   PubMed Web of Science ®Google Scholar
• Stüve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., Cook, L., Grand’Maison, F., Hemmer, B., Monson, N. L., and Racke, M. K. 2006. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 63:1383–1387.
   PubMed Web of Science ®Google Scholar
• TYSABRI. 2008. [Package insert]. Elan Pharmaceuticals, Inc. South San Francisco, CA; http://www.tysabri.com.
   Google Scholar
• Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., and Rutgeerts, P. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 353:362–368.
   PubMed Web of Science ®Google Scholar
• Willführ, K. U., Westermann, J., and Pabst, R. 1990. Absolute numbers of lymphocytes subsets migrating through the compartments of the normal and transplanted rat spleen. Eur. J. Immunol. 20:903–911.
   Google Scholar
• Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E. W., Jäger, H. R., and Clifford, D. B. 2006. Evaluation patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354:924–933.
   PubMed Web of Science ®Google Scholar